Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of CCT303-406 in HER2+ Solid Tumors
NCT04511871Phase 1Active, not recruiting
- Sponsor
- Shanghai PerHum Therapeutics
- Start
- Jul 2020
- Primary completion
- Oct 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DCTRS4-406 in solid tumor, gastric cancer (GC), breast cancer and 2 more, sponsored by Shanghai PerHum Therapeutics. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jul 2020; status: active, not recruiting.
02
Drugs
DCTRS4-406
03
Conditions
solid tumorgastric cancer (GC)breast cancerovarian cancersarcoma
Beyond the preview
Go deeper on NCT04511871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04511871.